WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoPreface
Ver el documentoIntroduction
Abrir esta carpeta y ver su contenidoParasitic infections
Abrir esta carpeta y ver su contenidoInsect and arachnid bites and stings
Abrir esta carpeta y ver su contenidoSuperficial fungal infections
Abrir esta carpeta y ver su contenidoSubcutaneous fungal infections
Abrir esta carpeta y ver su contenidoBacterial infections
Cerrar esta carpetaViral infections
Ver el documentoWarts
Ver el documentoHerpes simplex
Ver el documentoZoster and varicella
Ver el documentoMolluscum contagiosum
Abrir esta carpeta y ver su contenidoEczematous diseases
Abrir esta carpeta y ver su contenidoScaling diseases
Abrir esta carpeta y ver su contenidoPapulosquamous diseases
Ver el documentoCutaneous reactions to drugs
Abrir esta carpeta y ver su contenidoPigmentary disorders
Abrir esta carpeta y ver su contenidoPremalignant lesions and malignant tumours
Abrir esta carpeta y ver su contenidoPhotodermatoses
Abrir esta carpeta y ver su contenidoBullous dermatoses
Ver el documentoAlopecia areata
Ver el documentoUrticaria
Abrir esta carpeta y ver su contenidoConditions common in children
Ver el documentoAcne vulgaris
Ver el documentoPruritus
Ver el documentoTropical ulcers
Abrir esta carpeta y ver su contenidoAntimicrobial drugs
Abrir esta carpeta y ver su contenidoAntifugal drugs
Abrir esta carpeta y ver su contenidoAntiseptic agents
Abrir esta carpeta y ver su contenidoKeratoplastic and keratolytic agents
Abrir esta carpeta y ver su contenidoScabicides and pediculicides
Abrir esta carpeta y ver su contenidoAnti-inflammatory and antipruritic drugs1
Abrir esta carpeta y ver su contenidoAntiallergics and drugs used in anaphylaxis
Abrir esta carpeta y ver su contenidoUltraviolet radiation-blocking agents (sunscreens)
Abrir esta carpeta y ver su contenidoMiscellaneous drugs
Abrir esta carpeta y ver su contenidoAnnex
Ver el documentoSelected WHO Publications of Related Interest
Ver el documentoBack cover
 

Warts

Warts (verrucae) are caused by the human papillomavirus and may regress spontaneously at any time within months or years of their first appearance. However, particularly in immunosuppressed patients, they may become widespread and difficult to cure.

Treatment

Many common, plane and plantar warts can be left untreated, but painful or unsightly lesions generally respond to application of paints or lotions containing salicylic acid. Where available, liquid nitrogen applied with a cotton-tipped swab or a spray is highly effective. However, caution is required, since freezing can cause temporary or permanent depigmentation of the skin.

Genital warts (condylomata acuminata), which are transmitted by sexual contact, should always be treated, even though they frequently recur, since they may increase the risk of cervical cancer. Podophyllum resin, 10-25% in compound tincture of benzoin, should be applied carefully and sparingly to external genital, perianal and vaginal warts at weekly intervals up to a maximum of four applications; normal tissue should be avoided. Resin applied to the vaginal mucosa should be allowed to dry before it comes into contact with normal epithelium. Where it is available, podophyllotoxin is a less toxic alternative that can be applied by the patient. Trichloroacetic acid may be applied directly to the wart, but it is less effective and the treated area should be powdered with talc or sodium bicarbonate to remove excess acid.

External applications of podophyllum resin and podophyllotoxin should be removed by washing after 1-4 hours. Podophyllum resin is readily absorbed, locally destructive and teratogenic. Neither podophyllum resin nor podophyllotoxin should be applied to large skin surfaces, nor should they be used during pregnancy.

Surgical removal, electrocautery, cryosurgery and laser treatment may be used for genital warts when topical applications have failed or are contraindicated. Topical application of fluorouracil, 5% ointment, and intralesional or systemic administration of an interferon are also reported to be of value in resistant cases, but these treatments are expensive.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 19 enero 2012